743 related articles for article (PubMed ID: 28580511)
1. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
2. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
[TBL] [Abstract][Full Text] [Related]
3. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
4. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
5. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2015 Sep; 26(9):2273-80. PubMed ID: 25939310
[TBL] [Abstract][Full Text] [Related]
7. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
Xu S; Wang Y; Lu J; Xu J
Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
Szymczak J; Bohdanowicz-Pawlak A
Horm Metab Res; 2013 Sep; 45(10):759-64. PubMed ID: 23888411
[TBL] [Abstract][Full Text] [Related]
11. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
12. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
[TBL] [Abstract][Full Text] [Related]
14. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
[TBL] [Abstract][Full Text] [Related]
16. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
[TBL] [Abstract][Full Text] [Related]
17. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
Stern A; Laughlin GA; Bergstrom J; Barrett-Connor E
Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
[TBL] [Abstract][Full Text] [Related]
18. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
20. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]